Acutaas Chemicals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i2rpjqj8kwi09h16kla3qx33.pdf

Key Takeaways


The CDMO Engine: Pulled Forward and Doubled Down

Naresh Patel: "During our Q3 FY '25 Earnings Call, in January 2025, we had set our ambition of achieving Rs 1,000 crores in CDMO revenue by FY '28. Based on the current orders of existing as well as new CDMO contracts, we now believe we will achieve this target one year ahead of schedule. It means in FY '27, we will be achieving this Rs. 1,000 crores."

Financial Performance: Mix-Driven Margin Leap


New Growth Engines: Battery, Semiconductor, and BFC

Abhishek Patel: "We are not riding on some of the waves wherein price fluctuation, we don't want to get benefits from those price fluctuations or when it gets down. It is more of we look into our plate and we get our good profit wherein we get a timely payback of our investment and then look for a newer project."

Specialty Chemicals Transition: Phasing Out the Old


Margin Outlook: Upgraded on Mix Confidence

Naresh Patel: "In 5 years, this would be not known as a pharma company, but as a chemical company having multiple avenues, which can be applied, supply a chemical in a different sector." [13-14]

Visibility Gaps: What Management Would Not Quantify

Abhishek Patel: "We are very confident that we will be again able to achieve this second milestone of Rs. 2,000 crores revenue by FY '30 despite of any industry cycle moving up and down, we are confident that we will achieve those kind of revenue targets."

Guidance & Commitments

CommitmentSpecificsTimeline
CDMO revenue₹1,000 cr (pulled forward from FY28)FY27
CDMO revenue₹2,000 cr (doubling from ₹1,000 cr)FY30
Revenue growthAround 30% (revised from 25%)FY27
EBITDA margin38%-40% range (upgraded)FY27
CAPEX~₹300 cr full-yearFY27
Electronic-grade chemicals CAPEX~₹100 cr; production start by H1 FY29H2 FY27 CAPEX / H1 FY29 production
Electrolyte additive CAPEX~₹45 cr for second phaseH2 FY27
Battery Chemical ramp-upScale-up of third product; fourth product validation underwayNext 2-3 quarters
Semiconductor Chemicals revenueNo tall commitment for FY27; some revenue from FY28, slow rampFY28 onward
Ankleshwar Unit 2 utilizationLargely filled upFY28
Legacy commodity phase-out (Paraben/MS)Scale-down to take 1 to 1.5 years; MS may continue beyond1-1.5 years
CDMO pipeline commercialization8-9 products entering revenue streamNext 1 to 1.5 years

Key Metrics

MetricQ2 FY27
Revenue from operations₹436.9 cr, +42.7% YoY
Gross profit₹271.5 cr, +59% YoY
Gross margin62.1%, +637 bps YoY
EBITDA₹176 cr, +84.6% YoY
EBITDA margin40.3%, +914 bps YoY
PAT₹123.1 cr, +71.4% YoY
PAT margin28.2%, +472 bps YoY
Revenue growth guidance for FY27~30%, revised from 25%
EBITDA margin guidance for FY2738%–40%, raised from prior range
CDMO revenue target₹1,000 cr in FY27, achieved one year ahead of original FY28 target
CDMO revenue target by FY30₹2,000 cr, doubling in next 3 financial years
Advanced Pharma Intermediate segment revenue₹402 cr, +53.1% YoY
Core pharmaceutical business growth>25% YoY
Specialty Chemical segment revenue₹34.9 cr, −20% YoY
Ankleshwar unit utilization30% in Q2 FY27; expected not more than 40% by end of FY27
Working capital days115 days, vs 99 days in Q1 FY27
Net cash and cash equivalents~₹300.9 cr as of 30 Sep 2026
H1 FY27 CAPEX₹123.9 cr
Full-year FY27 CAPEX expected~₹300 cr
H2 FY27 planned CAPEX₹165 cr, comprising ~₹100 cr for electronic-grade chemicals, ₹45 cr for second phase of electrolyte additive CAPEX, remainder for maintenance